Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells

Nanoparticles represent useful drug delivery systems for the specific transport of drugs to tumour cells. In the present study biodegradable nanoparticles based on gelatin and human serum albumin (HSA) were developed. The surface of the nanoparticles was modified by covalent attachment of the biotin–binding protein NeutrAvidin™ enabling the binding of biotinylated drug targeting ligands by avidin–biotin-complex formation. Using the HER2 receptor specific antibody trastuzumab (Herceptin®) conjugated to the surface of these nanoparticles, a specific targeting to HER2-overexpressing cells could be shown. Attachment of the antibody-conjugated nanoparticles to the surface of HER2-overexpressing cells was time and dose dependent. Confocal laser scanning microscopy demonstrated an effective internalisation of the nanoparticles by HER2-overexpressing cells via receptor-mediated endocytosis. The results indicate that nanoparticles conjugated with an antibody against a specific tumour antigen holds promise, as selective drug delivery systems for the treatment of tumours expressing a specific tumour antigen. To our knowledge, this is the first study that demonstrates the effective and specific targeting of protein-based nanoparticles as drug delivery systems.

[1]  K. Strebhardt,et al.  Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. , 2004, Journal of the National Cancer Institute.

[2]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[3]  B. Rothen‐Rutishauser,et al.  Targeting her-2/neu with antirat Neu virosomes for cancer therapy. , 2002, Cancer research.

[4]  H. von Briesen,et al.  Human serum albumin-polyethylenimine nanoparticles for gene delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[5]  M. Wilchek,et al.  Biotin-containing reagents. , 1990, Methods in enzymology.

[6]  H. Gruber,et al.  Accurate measurement of avidin and streptavidin in crude biofluids with a new, optimized biotin-fluorescein conjugate. , 1999, Biochimica et biophysica acta.

[7]  K. Langer,et al.  Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. , 2000, International journal of pharmaceutics.

[8]  W. Pardridge,et al.  Receptor‐mediated delivery of an antisense gene to human brain cancer cells , 2002, The journal of gene medicine.

[9]  Marks,et al.  Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. , 2000, Pharmaceutical science & technology today.

[10]  J. Kreuter,et al.  Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake. , 2000, Journal of microencapsulation.

[11]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[12]  I. Ahmad,et al.  Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. , 1993, Cancer research.

[13]  K. Langer,et al.  Desolvation process and surface characterisation of protein nanoparticles. , 2000, International journal of pharmaceutics.

[14]  H von Briesen,et al.  Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  B. Genetet,et al.  A new immunoreagent for cell labeling. CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles. , 1988, Journal of immunological methods.

[16]  W. Tan,et al.  Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers. , 2001, Analytical chemistry.

[17]  P. Carter,et al.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.

[18]  K. Strebhardt,et al.  Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[19]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[20]  T. Nagai,et al.  Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. , 1988, Drug design and delivery.

[21]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[23]  Ulrik B Nielsen,et al.  Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.

[24]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  R. Bankert,et al.  Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. , 2000, Cancer research.